Search This Site:
Clinical Commissioning Groups Logo

JPC Bulletin

Bedfordshire and Luton Joint Prescribing Committee

Ref: JPC Bulletin 278
Bulletin Date: 27/09/19
Review Date: September 2021

Bulletin 278: Umeclidinium bromide (Incruse®Ellipta®) for the treatment of COPD

JPC Recommendations:

  • The committee agreed to add Umeclidinium bromide (Incruse®Ellipta®) to the formulary within its licensed indication as a 2nd choice LAMA option for the treatment of COPD.

Additional Information:

Scroll to Top